We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.81 | 799 | 11:27:16 |
By Allison Prang and Michael Tobin
AbbVie Inc. (ABBV) reported a drop in second-quarter profit as its earnings were hit by a noncash charge from a psoriasis treatment that gained regulatory approval.
The biopharmaceutical company said it had $741 million in net income, down 63% from the comparable quarter a year prior. Earnings per share were 49 cents, down from $1.26.
On an adjusted basis, earnings rose to $2.26 a share from $2 a share the same time last year. Analysts polled by FactSet estimated adjusted earnings of $2.21 a share.
AbbVie reported $8.26 billion in revenue, down 0.3%. Analysts estimated $8.1 billion in revenue.
The company said its estimate for future milestones and royalty payments as a result of psoriasis treatment Skyrizi being approved by the U.S. Food and Drug Administration and European Commission grew by $2.3 billion.
AbbVie on Friday also revised its earnings targets for this year. The company lowered its profit outlook to between $5.69 and $5.79 a share from between $7.26 and $7.36 a share. But excluding one-time items and noncash charges, AbbVie said it expects to generate a profit between $8.82 and $8.92 a share, compared with its prior forecast of posting an adjusted profit between $8.73 and $8.83 a share.
The earnings report comes after Abbvie last month agreed to buy drugmaker Allergan PLC in a roughly $63 billion deal.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
July 26, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions